261 completed, 41 recruiting, 32 unknown, 31 terminated. 419 Phase 3, 40 Phase 2.
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A FRSW107 - Severe Hemophilia A | Phase 3 | Not yet recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 76 | 2026-12-25 | 2024-06-20 |
| Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children NXT007 - Hemophilia A | Phase 3 | Recruiting | Hoffmann-La Roche | 50 | 2026-11-30 | 2026-11-13 |
| A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia Sutacimig - Thrombasthenia | Phase 3 | Recruiting | Hemab ApS | 76 | 2026-10-27 | 2026-11-13 |
| A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors marstacimab - Hemophilia A or B | Phase 3 | Recruiting | Pfizer | 95 | 2026-10-23 | 2026-11-09 |
| A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A Denecimig - Haemophilia A | Phase 3 | Recruiting | Novo Nordisk A/S | 84 | 2026-10-16 | 2026-10-28 |
| A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia SR604 - Hemophilia A, Hemophilia A and B | Phase 3 | Not yet recruiting | Shanghai RAAS Blood Products Co., Ltd. | 90 | 2026-09-30 | 2026-10-15 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-11-13 |
| SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis Emicizumab, FEIBA, rFVIIa - Hemophilia A | Phase 3 | Withdrawn | Emory University | 2026-09-01 | 2026-11-06 | |
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Amgen | 126 | 2026-08-21 | 2026-09-17 |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. FRSW107 - Severe Hemophilia A | Phase 3 | Active not recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 60 | 2026-06-12 | 2026-09-04 |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | Chinese SLE Treatment And Research Group | 164 | 2026-06-07 | 2026-06-18 |
| A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis Coagadex(R) - Acquired Factor X Deficiency | Phase 3 | Withdrawn | Kedrion S.p.A. | 2026-06-01 | 2026-11-05 | |
| ATRA for Management of Primary ITP all-trans retinoic acid (ATRA), Placebo - Immune Thrombocytopenia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 192 | 2026-05-30 | 2026-05-19 |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A NXT007, Human Coagulation Factor VIII - Hemophilia A | Phase 3 | Recruiting | Hoffmann-La Roche | 138 | 2026-05-15 | 2026-10-26 |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A NXT007, Emicizumab - Hemophilia A | Phase 3 | Recruiting | Hoffmann-La Roche | 360 | 2026-04-27 | 2026-11-03 |
| Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients QL0911, Placebo - Thrombocytopenia, Immune | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-04-20 | 2026-03-06 |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment FRSW107 - Severe Hemophilia A | Phase 3 | Active not recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 60 | 2026-04-14 | 2026-09-08 |
| High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia High-Dose Dexamethasone Combined with Orelabrutinib, High-Dose Dexamethasone Combined with Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | Shandong University | 86 | 2026-04-08 | 2026-04-30 |
| Safety of KN057 Prophylaxis in Patients With Haemophilia A or B KN057 - Hemophilia A or B | Phase 3 | Recruiting | Suzhou Alphamab Co., Ltd. | 70 | 2026-03-13 | 2026-04-22 |
| A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) - Hemophilia | Phase 3 | Recruiting | Sanofi | 85 | 2025-12-18 | 2026-10-27 |
Showing 20 of 419. Sign in to see all of them.
Hemophilia A (157) · Purpura, Thrombocytopenic, Idiopathic (120) · Hemophilia B (58) · Thrombocythemia, Essential (31) · Thrombocytopenia (26) · Hematologic Diseases (21) · von Willebrand Diseases (19) · Polycythemia Vera (18) · Primary Myelofibrosis (17) · Hemorrhage (16) · Hemorrhagic Disorders (16) · Lymphoma, Follicular (15) · Hemostatic Disorders (14) · Myeloproliferative Disorders (14)
Hemic and Lymphatic Diseases (418) · Hematologic Diseases (398) · Hemorrhagic Disorders (379) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (246) · Genetic Diseases, Inborn (233) · Blood Coagulation Disorders, Inherited (230) · Coagulation Protein Disorders (218) · Blood Platelet Disorders (181) · Pathological Conditions, Signs and Symptoms (170) · Pathologic Processes (167) · Signs and Symptoms (151) · Immune System Diseases (141) · Cytopenia (139) · Skin Manifestations (138)
Factor VIII (48) · Rituximab (18) · emicizumab (18) · Dexamethasone (17) · Immunoglobulins, Intravenous (15) · romiplostim (15) · F8 protein, human (13) · eltrombopag (13) · Factor IX (12) · Prednisone (8) · von Willebrand Factor (8) · BAX 855 (7) · Injections (7) · Thrombopoietin (7) · anagrelide (7)
Baxalta now part of Shire (30) · CSL Behring (24) · Novo Nordisk A/S (23) · Bio Products Laboratory (16) · Octapharma (16) · Shandong University (16) · Hoffmann-La Roche (13) · Pfizer (12) · Amgen (10) · Bayer (9) · Wyeth is now a wholly owned subsidiary of Pfizer (9) · Bioverativ Therapeutics Inc. (7) · Sanofi (7) · Takeda (7) · argenx (7)
United States (207) · United Kingdom (137) · Italy (125) · Spain (117) · Germany (115) · France (112) · Poland (98) · China (95) · Japan (94) · Canada (90) · Turkey (Türkiye) (79) · Australia (76) · Russia (70) · Austria (68) · Netherlands (65)
Ming Hou, Dr (5)
PMID 40750723, PMID 19216617, PMID 26196195, PMID 35939785, PMID 19005182, PMID 19671919, PMID 26931631, PMID 33995988, PMID 36848635, PMID 39091324, PMID 40386832, PMID 12944568, PMID 17077333, PMID 18242413, PMID 19846889, PMID 21533818, PMID 22117897, PMID 22494019, PMID 24335249, PMID 25273984, PMID 26679394, PMID 27002680, PMID 31697801, PMID 32293786, PMID 33275766, PMID 33719084, PMID 34922648, PMID 40099428, PMID 12401245, PMID 15459300, PMID 16973975, PMID 17397698, PMID 18208533, PMID 18510702, PMID 18625626, PMID 18689371, PMID 18697901, PMID 19386744, PMID 19635187, PMID 19731307, PMID 19776145, PMID 19787352, PMID 20130241, PMID 20237066, PMID 20719580, PMID 20841509, PMID 20863431, PMID 21628633, PMID 22409309, PMID 22476554
2023 (19), 2009 (11), 2016 (11), 2017 (9), 2019 (8), 2018 (6), 2008 (5), 2015 (5), 2025 (5), 2014 (4), 2004 (2), U01HL072268 (2), P01CA108671 (1), P30CA068485 (1), R01AG019147 (1)